Amneal Pharmaceuticals launched mesalamine 800 mg delayed-release tablets for UC and received FDA approval for various lenalidomide doses for blood cancers.

This analysis highlights the major risk factors resulting in limited use of oral JAKi for patients with hidradenitis suppurativa, including smoking, obesity, hypertension, and age.

Pitolisant was evaluated for the supplemental indication in the phase 3 INTUNE study, which did not meet its primary outcome of reducing excessive daytime sleepiness.

Chemomab completed an end-of-phase 2 meeting with the FDA and has aligned on the design of a phase 3 registration study for nebokitug (CM-101) in PSC.

HDV RNA-positive patients were more often diagnosed with advanced liver fibrosis and had a 4.7-fold greater risk of severe liver-related outcomes.

Data from 3 pooled phase 3 studies in children, adolescents, and adults will be presented at the AAAI/WAO Joint Congress.

Dual SGLT1/2 inhibition with sotagliflozin significantly reduced both heart attacks and stroke in a prespecified secondary analysis of the SCORED trial.

The February 18, 2025 SOCS News Update highlights SOCS mentorship opportunities as well as the importance of mentors and role models.

A study found many patients with chronic spontaneous urticaria need add-on or higher-dose therapies, revealing gaps in treatment. Findings will be presented at AAAAI 2025.

Alvotech and Teva expect the review to be completed in the fourth quarter of 2025.

Awarded to Luxa Biotechnology, early clinical from the first cohort of patients with dry AMD will be presented at an upcoming medical meeting.

A patient with decompensated liver cirrhosis treated with Namodenoson under a compassionate use program experienced improvements in disease at 20 months.

The FDA decision to approve the supplemental biologics license application for dupilumab (Dupixent) follows recent pivotal clinical trial data assessing 106 patients.

This analysis highlights the efficacy and safety of abrocitinib among patients with atopic dermatitis in China, as well as the medication’s impact on patients’ blood biomarkers.

Panelists discuss the safety of biologics in atopic dermatitis (AD), reviewing current understanding of their safety profiles, including long-term data, adverse events, and the overall risk-benefit analysis for patients using these agents.

Panelists discuss the frequency of combination therapy use in managing atopic dermatitis, highlighting its role in enhancing treatment efficacy and addressing multifactorial aspects of the disease in their patient population.

Younger age, low knowledge of HBV sequelae, and high perceived HBV stigma were linked to lower medication adherence in Korean American patients.

At week 12, a higher proportion of participants on rilzabrutinib 1200mg a day (60.9%) achieved AAS7 scores of 0 than placebo-treated participants (30.8%).

Large ASCVD randomized controlled trials in prominent journals often use heterogeneous endpoints, which could influence reported results.

These findings from the POETYK-PSO long-term extension trial point to a lack of new safety concerns in the first 5 years of using deucravacitinib for psoriasis.

A study found a 6-injection subcutaneous immunotherapy, Grass MATA MPL improves rhinitis quality of life by 27.7% and stimulates broad immune responses.

Female dialysis patients had a greater risk of infection- and withdrawal-related mortality, while men were more likely to die from cardiovascular disease and cancer.

Targeted Genomics’ GHR test uses NGS to detect genetic variants in genomic DNA isolated from at-home collected saliva samples.

In this episode, James Q. Del Rosso, DO, joins The Medical Sisterhood for a conversation about empowerment and the benefits of female role models.